Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

Video

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Steven Kaplan, MD, professor of Urology, Icahn School of Medicine at Mount Sinai, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).

Results from a study presented during the 2021 AUA Annual Meeting showed that real-world surgical retreatment rates are higher than what has previously been reported in this patient population, according to Kaplan. This is true even for standard procedures, such as transurethral resection of the prostate (TURP).

Results included that compared with TURP, GreenLight, and UroLift, patients who received Rezum steam injection experienced the highest rates of surgical retreatment in 1 year, Kaplan says.

These real-world data are important, as they may possess the potential to inform treatment decisions for these patients, Kaplan concludes. 

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD